Home › Companies › Galectin Therapeutics Inc. › 2025-2026
At Galectin Therapeutics Inc.'s shareholder meeting held December 3, 2025, in the 2025-2026 proxy season, 63 asset managers reported how they voted in their SEC Form N-PX filings, covering 338 separate fund positions. Their filings are grouped here into 15 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO VOTE ON A NON-BINDING ADVISORY RESOLUTION TO APPROVE THE COMPENSATION PAID TO GALECTIN'S… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Galectin Therapeutics Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on December 8, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Galectin Therapeutics Inc.’s Form 8-K, filed December 8, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of December 3, 2025: 13 items on Galectin Therapeutics Inc.’s Form 8-K, filed December 8, 2025: 11 elected · 2 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Galectin Therapeutics Inc. in the interactive database Compare manager voting policies
These tallies are Galectin Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed December 8, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Gilbert F. Amelio, Ph.D. | 25,335,421 | -- | -- | 874,903 | 19,513,532 | 97% | Elected | — |
| Elect Director: Benjamin S. Carson, Sr., M.D. | 25,916,838 | -- | -- | 293,486 | 19,513,532 | 99% | Elected | — |
| Elect Director: Kary Eldred | 25,886,740 | -- | -- | 323,584 | 19,513,532 | 99% | Elected | — |
| Elect Director: Kevin D. Freeman | 25,827,896 | -- | -- | 382,428 | 19,513,532 | 99% | Elected | — |
| Elect Director: Joel Lewis | 25,688,709 | -- | -- | 521,615 | 19,513,532 | 98% | Elected | — |
| Elect Director: Gilbert S. Omenn, M.D., Ph.D. | 25,810,287 | -- | -- | 400,037 | 19,513,532 | 98% | Elected | — |
| Elect Director: Marc Rubin, M.D. | 25,875,306 | -- | -- | 335,018 | 19,513,532 | 99% | Elected | — |
| Elect Director: Elissa J. Schwartz, Ph.D. | 25,920,970 | -- | -- | 289,354 | 19,513,532 | 99% | Elected | — |
| Elect Director: Harold H. Shlevin, Ph.D. | 25,745,010 | -- | -- | 465,314 | 19,513,532 | 98% | Elected | — |
| Elect Director: Richard E. Uihlein, Chairman | 25,907,034 | -- | -- | 303,290 | 19,513,532 | 99% | Elected | — |
| Elect Director: Richard A. Zordani | 25,906,350 | -- | -- | 303,974 | 19,513,532 | 99% | Elected | — |
| Vote on a non-binding advisory resolution to approve the compensation paid to Galectin's named executive officers, as disclosed in the proxy statement | 25,260,489 | 639,415 | 310,420 | -- | 19,513,532 | 98% | Not verified | — |
| - 2 - Recommendation, by non-binding vote, the frequency with which Galectin will conduct stockholder advisory votes on executive compensation | 45,458,024 | 142,268 | 123,564 | -- | -- | 99.6% | Not verified | — |
Source: Galectin Therapeutics Inc., Form 8-K, filed with the SEC on December 8, 2025 — read the filing on EDGAR.
Each item below shows how the 63 asset managers that disclosed a Galectin Therapeutics Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Galectin Therapeutics Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Benjamin S. Carson, Sr., M.D.
Galectin Therapeutics Inc.’s own tally for this item (“Elect Director: Benjamin S. Carson, Sr., M.D.”): 25,916,838 for, 293,486 withheld, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 262,844 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| Northern Trust | 5,420 | 0 | 0 | 0 | For |
| BlackRock | 4,764 | 0 | 0 | 0 | For |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 858 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 198 | 0 | 0 | 0 | For |
| John Hancock | 77 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Elissa J. Schwartz, Ph.D.
Galectin Therapeutics Inc.’s own tally for this item (“Elect Director: Elissa J. Schwartz, Ph.D.”): 25,920,970 for, 289,354 withheld, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 262,646 for, 198 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| Northern Trust | 5,420 | 0 | 0 | 0 | For |
| BlackRock | 4,764 | 0 | 0 | 0 | For |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 858 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 198 | Withhold |
| John Hancock | 77 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Gilbert F. Amelio, Ph.D.
Galectin Therapeutics Inc.’s own tally for this item (“Elect Director: Gilbert F. Amelio, Ph.D.”): 25,335,421 for, 874,903 withheld, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 251,604 for, 6,476 withheld, 4,764 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 5,420 | Withhold |
| BlackRock | 0 | 0 | 4,764 | 0 | Abstain |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 0 | 858 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 198 | Withhold |
| John Hancock | 77 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Gilbert S. Omenn, M.D.
Galectin Therapeutics Inc.’s own tally for this item (“Elect Director: Gilbert S. Omenn, M.D., Ph.D.”): 25,810,287 for, 400,037 withheld, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 262,646 for, 198 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| Northern Trust | 5,420 | 0 | 0 | 0 | For |
| BlackRock | 4,764 | 0 | 0 | 0 | For |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 858 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 198 | Withhold |
| John Hancock | 77 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Harold H. Shlevin, Ph.D.
Galectin Therapeutics Inc.’s own tally for this item (“Elect Director: Harold H. Shlevin, Ph.D.”): 25,745,010 for, 465,314 withheld, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 262,646 for, 198 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| Northern Trust | 5,420 | 0 | 0 | 0 | For |
| BlackRock | 4,764 | 0 | 0 | 0 | For |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 858 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 198 | Withhold |
| John Hancock | 77 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Joel Lewis
Galectin Therapeutics Inc.’s own tally for this item (“Elect Director: Joel Lewis”): 25,688,709 for, 521,615 withheld, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 262,646 for, 198 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| Northern Trust | 5,420 | 0 | 0 | 0 | For |
| BlackRock | 4,764 | 0 | 0 | 0 | For |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 858 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 198 | Withhold |
| John Hancock | 77 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Kary Eldred
Galectin Therapeutics Inc.’s own tally for this item (“Elect Director: Kary Eldred”): 25,886,740 for, 323,584 withheld, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 262,646 for, 198 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| Northern Trust | 5,420 | 0 | 0 | 0 | For |
| BlackRock | 4,764 | 0 | 0 | 0 | For |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 858 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 198 | Withhold |
| John Hancock | 77 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Kevin D. Freeman
Galectin Therapeutics Inc.’s own tally for this item (“Elect Director: Kevin D. Freeman”): 25,827,896 for, 382,428 withheld, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 262,646 for, 198 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| Northern Trust | 5,420 | 0 | 0 | 0 | For |
| BlackRock | 4,764 | 0 | 0 | 0 | For |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 858 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 198 | Withhold |
| John Hancock | 77 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Marc Rubin, M.D.
Galectin Therapeutics Inc.’s own tally for this item (“Elect Director: Marc Rubin, M.D.”): 25,875,306 for, 335,018 withheld, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 262,646 for, 198 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| Northern Trust | 5,420 | 0 | 0 | 0 | For |
| BlackRock | 4,764 | 0 | 0 | 0 | For |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 858 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 198 | Withhold |
| John Hancock | 77 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Richard A. Zordani
Galectin Therapeutics Inc.’s own tally for this item (“Elect Director: Richard A. Zordani”): 25,906,350 for, 303,974 withheld, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 262,646 for, 198 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| Northern Trust | 5,420 | 0 | 0 | 0 | For |
| BlackRock | 4,764 | 0 | 0 | 0 | For |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 858 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 198 | Withhold |
| John Hancock | 77 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Richard E. Uihlein
Galectin Therapeutics Inc.’s own tally for this item (“Elect Director: Richard E. Uihlein, Chairman”): 25,907,034 for, 303,290 withheld, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 262,646 for, 198 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| Northern Trust | 5,420 | 0 | 0 | 0 | For |
| BlackRock | 4,764 | 0 | 0 | 0 | For |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 858 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 198 | Withhold |
| John Hancock | 77 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: TO VOTE ON A NON-BINDING ADVISORY RESOLUTION TO APPROVE THE COMPENSATION PAID TO GALECTIN'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT ACCOMPANYING THIS LETTER.
Galectin Therapeutics Inc.’s own tally for this item (“Vote on a non-binding advisory resolution to approve the compensation paid to Galectin's named executive officers, as disclosed in the proxy statement”): 25,260,489 for, 639,415 against, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| Northern Trust | 5,420 | 0 | 0 | 0 | For |
| BlackRock | 4,764 | 0 | 0 | 0 | For |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 858 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 198 | 0 | 0 | 0 | For |
| John Hancock | 77 | 0 | 0 | 0 | For |
Fund voting reports, all 8 managers: 262,844 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| DEBUSSY CAPITAL MANAGEMENT LP | 316,215 | 0 | 0 | 0 | For |
| State Street | 116,540 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 77,862 | 0 | 0 | 0 | For |
| BlackRock | 70,041 | 964 | 0 | 0 | For |
| TRUIST FINANCIAL CORP | 68,000 | 0 | 0 | 0 | For |
| Ancora Advisors LLC | 65,600 | 0 | 0 | 0 | For |
| Citadel | 61,355 | 0 | 0 | 0 | For |
| BLAIR WILLIAM & CO/IL | 57,092 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 56,951 | 0 | 0 | 0 | For |
| Northern Trust | 53,089 | 0 | 0 | 0 | For |
| Sanctuary Advisors, LLC | 50,585 | 0 | 0 | 0 | For |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 34,910 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 29,700 | 0 | 0 | 0 | For |
| Focus Partners Wealth | 24,198 | 653 | 0 | 0 | For |
| Charles Schwab | 23,976 | 0 | 0 | 0 | For |
| Point72 | 18,059 | 0 | 0 | 0 | For |
| Two Sigma | 16,612 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 14,826 | 0 | 0 | 0 | For |
| Fidelity | 12,657 | 0 | 0 | 0 | For |
| Summit Trail Advisors, LLC | 10,991 | 0 | 0 | 0 | For |
| STOCK YARDS BANK & TRUST CO | 10,500 | 0 | 0 | 0 | For |
| ATWOOD & PALMER INC | 10,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 8,136 | 0 | 0 | 0 | For |
| Colony Family Offices, LLC | 7,675 | 0 | 0 | 0 | For |
| NORRIS PERNE & FRENCH LLP/MI | 7,500 | 0 | 0 | 0 | For |
Institutional-manager reports, all 59 managers: 1,267,053 for, 4,252 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: TO RECOMMEND, BY NON-BINDING VOTE, THE FREQUENCY WITH WHICH GALECTIN WILL CONDUCT STOCKHOLDER ADVISORY VOTES ON EXECUTIVE COMPENSATION.
Galectin Therapeutics Inc.’s own tally for this item (“- 2 - Recommendation, by non-binding vote, the frequency with which Galectin will conduct stockholder advisory votes on executive compensation”): 45,458,024 for, 142,268 against, per its Form 8-K filed December 8, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 8 managers: 262,844 1 year.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| DEBUSSY CAPITAL MANAGEMENT LP | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| MARSHALL WACE, LLP | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| TRUIST FINANCIAL CORP | 0 | 0 | 0 | 0 | -- |
| Ancora Advisors LLC | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| BLAIR WILLIAM & CO/IL | 0 | 0 | 0 | 0 | -- |
| Fisher Asset Management, LLC | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Sanctuary Advisors, LLC | 0 | 0 | 0 | 0 | -- |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 0 | 0 | 0 | 0 | -- |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 0 | 0 | 0 | -- |
| Focus Partners Wealth | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Point72 | 0 | 0 | 0 | 0 | -- |
| Two Sigma | 0 | 0 | 0 | 0 | -- |
| Hudson Bay Capital Management LP | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Summit Trail Advisors, LLC | 0 | 0 | 0 | 0 | -- |
| STOCK YARDS BANK & TRUST CO | 0 | 0 | 0 | 0 | -- |
| ATWOOD & PALMER INC | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Colony Family Offices, LLC | 0 | 0 | 0 | 0 | -- |
| NORRIS PERNE & FRENCH LLP/MI | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 58 managers: 1,500 for, 1,181,820 1 year, 82,307 3 year, 6,653 2 year. Showing the 25 largest; every one is in the interactive database (link above).
99.3% of fund votes cast · no official result
Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF CHERRY BEKAERT LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
The 4 asset managers below reported 28,811 for, 198 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Charles Schwab | 23,970 | 0 | 0 | 0 | For |
| BlackRock | 4,764 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 198 | 0 | 0 | Against |
| John Hancock | 77 | 0 | 0 | 0 | For |
100% of fund votes cast · no official result
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Chery Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
The 4 asset managers below reported 233,835 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 223,281 | 0 | 0 | 0 | For |
| Northern Trust | 5,420 | 0 | 0 | 0 | For |
| Fidelity | 4,276 | 0 | 0 | 0 | For |
| Equitable | 858 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 64,472,792 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 0.35% |
| 2 | Charles Schwab | 0.04% |
| 3 | Northern Trust | <0.01% |
| 4 | BlackRock | <0.01% |
| 5 | Fidelity | <0.01% |
| 6 | Equitable | <0.01% |
| 7 | Advisors' Inner Circle Fund III | <0.01% |
| 8 | John Hancock | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | DEBUSSY CAPITAL MANAGEMENT LP | 0.49% |
| 2 | State Street | 0.18% |
| 3 | MARSHALL WACE, LLP | 0.12% |
| 4 | BlackRock | 0.11% |
| 5 | TRUIST FINANCIAL CORP | 0.11% |
| 6 | Ancora Advisors LLC | 0.10% |
| 7 | Citadel | 0.10% |
| 8 | BLAIR WILLIAM & CO/IL | 0.09% |
| 9 | Fisher Asset Management, LLC | 0.09% |
| 10 | Northern Trust | 0.08% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Richard E. Uihlein | — | 13D |
| James C. Czirr | — | DEF14A |
| 10X Fund, L.P. | — | DEF14A |
| Vanguard Group | — | 13F |
| Joel Lewis | — | DEF14A |
| Kary Eldred | — | DEF14A |
| Kevin Freeman | — | DEF14A |
| BlackRock | — | 13F |
| Millennium Management | — | 13F |
| Geode Capital | — | 13F |
Percentages above are of 64,472,792 shares outstanding, as reported by Galectin Therapeutics Inc. on its Form 10-Q dated November 7, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Galectin Therapeutics Inc.’s 10-Q dated November 7, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Galectin Therapeutics Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Galectin Therapeutics (GALT) 2025 Annual Meeting (2025-2026 season)”, https://proxyvotesnow.com/company/galectin-therapeutics-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.